Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.38 |
| ▸ | CDK9 | P50750 | 6/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.34 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10282687 | 0.96 | BRD4 (0.43) | BRD4PI4KBCCNT1CDK9MAPK14 | |
| SCHEMBL10275539 | 0.85 | FLT3 (0.39) | ALK | |
| SCHEMBL10313875 | 0.84 | BRD4 (0.39) | BRD4PI4KBCCNT1CDK9MAPK14 | |
| SCHEMBL10275574 | 0.84 | BRD4 (0.39) | BRD4CCNT1CDK9IDH1LRRK2 | |
| SCHEMBL10276207 | 0.83 | BRD4 (0.43) | BRD4PI4KBCCNT1CDK9MAPK14 | |
| SCHEMBL10276540 | 0.82 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL10276148 | 0.81 | BRD4 (0.41) | BRD4PI4KBCCNT1CDK9IDH1 | |
| SCHEMBL10276292 | 0.81 | BRD4 (0.43) | BRD4PI4KBCCNT1CDK9MAPK14 | |
| SCHEMBL10282686 | 0.81 | FNTA (0.34) | MAPK14ALKSLC2A1SLC2A3SLC2A4 | |
| SCHEMBL10313803 | 0.78 | BRD4 (0.40) | BRD4PI4KBMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | BRD4 3228/4885PI4KB 3384/4885CCNT1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.